Open Beta
TREN
MetriLume
TREN

US marketsAVTX

SEC-sourced researchBeta

AVTX

Avalo Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001534120
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Oct 2, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 441,000.0000 USD; December 2025: 59,000.0000 USD441K USD0 USD0December 2024December 2025
AVTX · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2024441,000.0000Mar 23, 2026
December 202559,000.0000Mar 23, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202559,000.0000-78,259,000.0000-51,458,000.0000116,458,000.000033,409,000.0000Mar 23, 2026
December 2024441,000.0000-35,129,000.0000-49,056,000.0000150,732,000.000017,700,000.0000Mar 23, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

34/100
Profitability0
Growth0
Balance sheet71
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$59KJan 1, 2025 – Dec 31, 2025Mar 23, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$441KJan 1, 2024 – Dec 31, 2024Mar 23, 202610-K
Net incomeNetIncomeLoss-$78.26MJan 1, 2025 – Dec 31, 2025Mar 23, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$51.46MJan 1, 2025 – Dec 31, 2025Mar 23, 202610-K
Total assetsAssets$116.46MDec 31, 2025Mar 23, 202610-K
Total liabilitiesLiabilities$33.41MDec 31, 2025Mar 23, 202610-K

New filings

Explore methodology ↗